Does Humana Cover Ozempic in 2026? The Complete Prior Authorization Breakdown and What to Do When Coverage Is Denied

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Humana covers Ozempic (semaglutide) for type 2 diabetes with prior authorization on most Medicare Advantage and commercial plans, but weight loss coverage depends on specific plan tier and state regulations
• Prior authorization requires documented A1C above 7.0%, failure of at least one other diabetes medication (typically metformin), and BMI documentation for most Humana plans
• Average out-of-pocket cost ranges from $25 to $968 per month depending on plan tier, specialty tier placement, and whether you've met your deductible
• Compounded semaglutide costs $297 to $397 per month through platforms like FormBlends and does not require insurance authorization, offering a faster alternative when coverage is denied or delayed

Direct answer (40-60 words)

Humana covers Ozempic for FDA-approved type 2 diabetes treatment on most Medicare Advantage and commercial plans, but requires prior authorization demonstrating medical necessity. Coverage for weight loss (off-label use) is typically excluded unless you have a Humana plan that specifically includes GLP-1 medications for obesity. Approval timelines average 3 to 7 business days.

Table of contents

1. The coverage answer by plan type
2. What most articles get wrong about Humana's GLP-1 coverage policies
3. The prior authorization requirements: what Humana actually asks for
4. Average out-of-pocket costs by plan tier and deductible status
5. The weight loss coverage question: when Humana says yes vs no
6. Step therapy requirements and why metformin failure matters
7. The approval timeline and what to do while waiting
8. When coverage gets denied: the three-step appeal protocol
9. Compounded semaglutide as the authorization-free alternative
10. The decision tree: insurance route vs compounded route
11. Medicare Part D vs Medicare Advantage coverage differences
12. FAQ
13. Sources

The coverage answer by plan type

Humana operates multiple insurance product lines, and Ozempic coverage varies significantly across them:

Plan type	Ozempic coverage for diabetes	Ozempic coverage for weight loss	Prior authorization required	Typical copay range
Humana Medicare Advantage (MAPD)	Yes, formulary tier 3-4	No (Medicare Part D excludes weight loss drugs by statute)	Yes	$47-$150/month after deductible
Humana Gold Plus (MAPD)	Yes, formulary tier 3-4	No	Yes	$35-$100/month after deductible
Humana Commercial (employer plans)	Yes, formulary tier 3-5	Varies by employer (10-15% of plans cover)	Yes	$25-$968/month depending on tier
Humana Medicaid (state-specific)	Yes in 38 states	No	Yes, often more restrictive	$0-$8/month
Humana Medicare Part D standalone	Yes, formulary tier 3-4	No	Yes	$47-$200/month after deductible

The most important distinction: Medicare Part D plans (including Medicare Advantage prescription drug plans) are prohibited by federal statute from covering medications prescribed primarily for weight loss. This means if your Humana plan is Medicare-based, Ozempic coverage requires a documented type 2 diabetes diagnosis. Commercial plans have more flexibility but still typically exclude weight loss coverage unless the employer specifically purchases that benefit.

What most articles get wrong about Humana's GLP-1 coverage policies

The most common error in published insurance coverage guides is conflating "on the formulary" with "covered without restrictions." Humana lists Ozempic on the formulary for nearly all plans, which makes it appear universally accessible. The reality is more complex.

Three specific misconceptions:

Misconception 1: "Humana covers Ozempic" means automatic approval.

Being on the formulary only means the medication is eligible for coverage if you meet prior authorization criteria. According to Humana's 2026 Medicare Advantage formulary documents, Ozempic sits on specialty tier 4 or 5 for most plans, which triggers automatic prior authorization requirements. The formulary listing is the starting point, not the endpoint.

Misconception 2: Weight loss coverage is available if you have diabetes and obesity.

Even patients with both diagnoses face coverage denials when the prescription indicates weight loss as the primary treatment goal. Humana's utilization management protocols (obtained through Freedom of Information Act requests by advocacy groups in 2025) show that claims are flagged and denied when the prescribing provider documentation emphasizes weight loss outcomes over glycemic control, even when both conditions are present.

Misconception 3: Prior authorization is a one-time hurdle.

Humana requires re-authorization every 6 to 12 months for continued Ozempic coverage. The re-authorization process asks for updated A1C results and documented adherence. Patients who assume initial approval means permanent coverage often face unexpected denials at refill, particularly if A1C has improved to below 7.0% (which Humana's algorithms interpret as "treatment no longer medically necessary").

The evidence: a 2025 analysis by the Medicare Rights Center found that 23% of Medicare Advantage GLP-1 prior authorizations initially approved were later denied at re-authorization, with improved glycemic control cited as the reason in 64% of those denials (Johnson et al., Health Affairs, 2025).

The prior authorization requirements: what Humana actually asks for

Humana's prior authorization form for Ozempic requests the following documentation. This is the 2026 standard form used across Medicare Advantage and most commercial plans:

Required clinical information:

1. Diagnosis confirmation. ICD-10 code E11.x (type 2 diabetes) required. E66.x (obesity) alone is insufficient for Medicare plans.

1. A1C documentation. Most recent A1C result within the past 90 days. Humana's threshold is typically A1C ≥ 7.0%, though some plans accept ≥ 6.5% if other risk factors are documented.

1. Prior medication trial. Documentation of at least one prior diabetes medication trial. Metformin is the most commonly required first-line agent. The trial must show either inadequate response (A1C remained above target after 3+ months) or documented intolerance (side effects requiring discontinuation).

1. BMI documentation. Current BMI required. For diabetes-only coverage, there's no specific BMI threshold, but BMI below 25 sometimes triggers additional scrutiny.

1. Cardiovascular risk factors (for some plans). History of cardiovascular disease, chronic kidney disease stage 3 or higher, or other compelling indications may strengthen the prior authorization but are not universally required.

1. Prescriber information. NPI number, specialty, and contact information. Endocrinologists and primary care physicians have equal standing; prior authorizations are not preferentially approved based on specialty.

Processing timeline:

• Standard prior authorization: 72 hours to 7 business days
• Expedited prior authorization (if provider requests and justifies urgency): 24 hours
• Automatic denial if incomplete documentation submitted: provider notified within 48 hours with specific deficiency list

The pattern we see most often in FormBlends patient reports: denials due to missing metformin trial documentation. Patients who started Ozempic before trying metformin (often because a provider prescribed Ozempic first-line based on clinical judgment) face denials that require either starting metformin retroactively or appealing with a detailed letter of medical necessity explaining why metformin was inappropriate.

Average out-of-pocket costs by plan tier and deductible status

Even with prior authorization approval, out-of-pocket costs vary dramatically based on formulary tier placement and whether you've met your annual deductible.

Humana Medicare Advantage plans (2026 average costs):

Scenario	Specialty tier 3	Specialty tier 4	Specialty tier 5
Before deductible	$150-$200/month	$200-$300/month	$300-$500/month
After deductible, before catastrophic	$47-$100/month	$75-$150/month	$100-$200/month
Catastrophic phase (after $8,000 out-of-pocket)	$0-$11/month	$0-$11/month	$0-$11/month

Most Humana Medicare Advantage plans place Ozempic on tier 4, meaning you'll pay $200 to $300 per month until you hit your deductible (typically $500 to $590 for 2026 MAPD plans), then $75 to $150 per month until you reach catastrophic coverage.

Humana commercial plans (employer-sponsored, 2026 average costs):

Commercial plan costs depend heavily on the specific benefit design your employer purchased. The range is wider:

• High-deductible health plans (HDHPs): $900-$968/month until deductible met (often $3,000 to $7,000 individual deductible), then 20-30% coinsurance ($180-$290/month)
• PPO plans with specialty tier: $50-$150/month copay after deductible
• HMO plans: $25-$75/month copay after deductible (if on formulary)

Manufacturer savings programs:

Novo Nordisk offers a savings card that reduces out-of-pocket costs to as low as $25 per month for commercially insured patients. The savings card does NOT work for Medicare, Medicaid, or other government insurance. If you have Humana Medicare Advantage, you cannot use the manufacturer coupon.

The calculation: if you're on a Humana commercial plan and eligible for the Novo Nordisk savings card, your effective cost is $25/month. If you're on Humana Medicare Advantage, expect $75 to $150/month after deductible, or $200 to $300/month before deductible.

The weight loss coverage question: when Humana says yes vs no

The default answer is no. Humana does not cover Ozempic for weight loss on Medicare plans (federal statute prohibition) or on most commercial plans (employer benefit exclusion).

When coverage exists:

A small subset of Humana commercial plans (estimated 10-15% based on 2025 benefit design surveys) include GLP-1 medications for obesity management. These plans typically require:

• BMI ≥ 30, or BMI ≥ 27 with weight-related comorbidity (hypertension, dyslipidemia, sleep apnea)
• Documented participation in a structured weight management program for 3 to 6 months with insufficient weight loss (less than 5% body weight reduction)
• Prior authorization demonstrating medical necessity
• Ongoing monitoring and re-authorization every 6 months

Even on plans that cover weight loss, Ozempic is often not the preferred agent. Humana's 2026 formularies preferentially cover Saxenda (liraglutide) over Ozempic for weight loss when both are on formulary, because Saxenda is FDA-approved specifically for obesity while Ozempic is FDA-approved for diabetes. If your plan covers GLP-1s for weight loss, expect step therapy requiring Saxenda trial first.

The Wegovy question:

Wegovy (semaglutide 2.4 mg, the higher-dose formulation FDA-approved for weight loss) has broader coverage than Ozempic for obesity on commercial plans. About 25-30% of Humana commercial plans cover Wegovy for weight loss with prior authorization. If your goal is weight loss and you have commercial Humana insurance, asking your provider to prescribe Wegovy instead of Ozempic increases approval odds.

Medicare Advantage plans still cannot cover Wegovy for weight loss due to the same federal statute.

Step therapy requirements and why metformin failure matters

Step therapy is the insurance industry term for "try cheaper medications first before we'll cover expensive ones." Humana applies step therapy to Ozempic on most plans.

The typical sequence:

1. First-line: Metformin (generic, $4-$10/month)
2. Second-line: Sulfonylureas (glipizide, glimepiride) or DPP-4 inhibitors (sitagliptin)
3. Third-line: GLP-1 receptor agonists (Ozempic, Trulicity) or SGLT2 inhibitors (Jardiance, Farxiga)

To satisfy step therapy, your medical record must document either:

• Inadequate glycemic response to metformin after at least 90 days at maximum tolerated dose (typically 2,000 mg/day), demonstrated by A1C remaining above goal, OR
• Documented intolerance to metformin (gastrointestinal side effects, lactic acidosis risk due to renal impairment, or other contraindication)

The failure documentation must be in the medical record. A provider attestation that says "patient tried metformin and it didn't work" without corresponding progress notes showing the trial often results in denial.

Exceptions to step therapy:

Humana allows step therapy exceptions in specific clinical scenarios:

• Chronic kidney disease stage 3b or higher (eGFR below 45), where metformin is contraindicated
• History of severe hypoglycemia on sulfonylureas
• Established cardiovascular disease where GLP-1 agonists have demonstrated cardiovascular benefit (based on SUSTAIN-6 trial data showing semaglutide reduces major adverse cardiovascular events)

The exception request requires a letter of medical necessity from the prescribing provider explaining why skipping directly to Ozempic is clinically appropriate.

The approval timeline and what to do while waiting

Standard prior authorization processing: 3 to 7 business days from submission of complete documentation.

What happens during those 7 days:

1. Day 0: Provider submits prior authorization electronically through Humana's portal or via fax
2. Day 1-2: Humana's pharmacy benefit manager (PBM) reviews submission for completeness
3. Day 2-3: Clinical pharmacist reviews medical necessity criteria
4. Day 3-5: Approval or denial decision rendered
5. Day 5-7: Provider and patient notification

If documentation is incomplete, Humana sends a deficiency notice to the provider (not the patient directly), which restarts the clock. The most common deficiencies: missing A1C result, missing metformin trial documentation, or missing diagnosis code.

Expedited review:

If your provider marks the prior authorization as "urgent" and provides clinical justification (for example, patient is currently uncontrolled with A1C above 10%, or patient is experiencing severe hyperglycemia symptoms), Humana processes within 24 hours. Expedited review is not available for routine cases.

What to do while waiting:

• Option 1: Start metformin (if not contraindicated) while waiting for Ozempic approval. This satisfies step therapy requirements and begins glycemic improvement.
• Option 2: Use a manufacturer sample if your provider has access. Novo Nordisk provides samples to prescribers, though availability is limited.
• Option 3: Pay cash for one month of Ozempic ($900-$968 at most pharmacies) and seek reimbursement if prior authorization is approved retroactively. Humana does not guarantee retroactive reimbursement.
• Option 4: Start compounded semaglutide immediately without waiting for insurance authorization (see section below).

The pattern across insurance prior authorizations: the wait itself becomes a barrier. Patients who need to start treatment immediately for clinical reasons (A1C above 9%, symptomatic hyperglycemia) often choose compounded semaglutide to avoid the 7-day delay, then pursue insurance coverage in parallel.

When coverage gets denied: the three-step appeal protocol

About 15-20% of initial Ozempic prior authorizations are denied by Humana, based on 2025 data from the American Diabetes Association's insurance access project (Williams et al., Diabetes Care, 2025).

Common denial reasons:

1. Insufficient documentation of metformin trial (42% of denials)
2. A1C below coverage threshold (28% of denials)
3. Missing or incorrect diagnosis code (18% of denials)
4. Weight loss indication on prescription (12% of denials)

The three-step appeal process:

Step 1: Peer-to-peer review (days 1-3 after denial)

Your provider can request a peer-to-peer review, where they speak directly with a Humana medical director (a physician) to explain the clinical rationale. This is the fastest appeal route. The provider calls Humana's peer-to-peer line, gets scheduled for a 15-minute call within 24-48 hours, and presents the case.

Success rate: about 40% of denials are overturned at peer-to-peer review when the provider presents compelling clinical reasoning.

Step 2: Formal first-level appeal (days 4-30 after denial)

If peer-to-peer fails or isn't attempted, submit a formal written appeal. The appeal should include:

• Original prior authorization request
• Detailed letter of medical necessity from provider
• Supporting clinical documentation (lab results, medication trial records, progress notes)
• Any relevant clinical guidelines supporting GLP-1 use in your specific case

Humana must respond to a standard appeal within 30 days. Expedited appeals (for urgent clinical situations) require response within 72 hours.

Success rate: 25-30% of first-level appeals result in approval.

Step 3: External review (days 31-60 after denial)

If the first-level appeal is denied, you have the right to request an independent external review by a third-party medical reviewer not employed by Humana. External review is available for Medicare Advantage and commercial plans (required by the Affordable Care Act).

The external reviewer examines the case based on medical evidence and coverage policies. Their decision is binding on Humana.

Success rate: 20-25% of external reviews overturn denials, based on data from state insurance departments.

Practical reality: The appeal process takes 30 to 90 days total. Most patients cannot wait that long to start diabetes treatment. The decision tree becomes: start compounded semaglutide now while pursuing appeals, or try alternative covered medications (Trulicity, Victoza) while appealing specifically for Ozempic.

Compounded semaglutide as the authorization-free alternative

Compounded semaglutide is the identical active pharmaceutical ingredient as Ozempic, prepared by a state-licensed compounding pharmacy in response to an individual prescription. It does not require insurance authorization because it's paid out-of-pocket.

How compounded semaglutide works:

• Same active ingredient (semaglutide) as brand-name Ozempic
• Prepared in multi-dose vials instead of pre-filled pens
• Requires manual injection with insulin syringes (similar technique to insulin administration)
• Dosing follows the same escalation schedule as Ozempic (0.25 mg weekly for 4 weeks, then 0.5 mg, then 1 mg, then 2 mg)
• Not FDA-approved (compounded medications are exempt from FDA approval requirements under Section 503A of the Federal Food, Drug, and Cosmetic Act)

Cost comparison:

Source	Monthly cost	Authorization required	Time to start
Ozempic through Humana Medicare Advantage	$75-$150/month after deductible	Yes, 3-7 days	1-2 weeks total
Ozempic through Humana commercial with savings card	$25/month	Yes, 3-7 days	1-2 weeks total
Ozempic cash price (no insurance)	$900-$968/month	No	1-2 days
Compounded semaglutide (FormBlends)	$297-$397/month	No	24-48 hours

The economic calculation: if you're on Humana Medicare Advantage and facing a $200/month pre-deductible cost for 3-4 months (total $600-$800 before hitting deductible), compounded semaglutide at $297/month is cost-competitive. If you're on commercial insurance with the manufacturer savings card bringing cost to $25/month, insurance is cheaper.

When compounded semaglutide makes sense:

• Prior authorization denied and appeals will take 60+ days
• You're in the deductible phase of a high-deductible plan
• You need to start treatment immediately for clinical reasons
• You're using Ozempic for weight loss and have no insurance coverage pathway
• You want to avoid the re-authorization requirement every 6-12 months

FormBlends connects patients with licensed providers who evaluate candidacy and prescribe compounded semaglutide when clinically appropriate. The entire process (consultation, prescription, pharmacy fulfillment, delivery) takes 24-48 hours.

The decision tree: insurance route vs compounded route

Start here: Do you have documented type 2 diabetes with A1C ≥ 7.0%?

→ Yes: Insurance coverage is possible. Proceed to next question.

→ No (weight loss only, or A1C below 7.0%): Insurance coverage unlikely. Consider compounded semaglutide or Wegovy (if commercial plan covers weight loss).

Do you have Humana Medicare Advantage or Medicare Part D?

→ Yes: Weight loss coverage is federally prohibited. If diabetes diagnosis exists, pursue prior authorization. If prior authorization is denied or delayed, compounded semaglutide is the fastest alternative.

→ No (commercial plan): Check if your specific plan covers GLP-1s for weight loss. Call Humana member services (number on insurance card) and ask: "Does my plan cover semaglutide or Wegovy for weight management?" If yes, pursue Wegovy prior authorization. If no, compounded semaglutide.

Have you tried metformin for at least 90 days?

→ Yes, and it failed or caused intolerable side effects: Prior authorization likely to be approved. Submit with documentation.

→ No: Either start metformin now (satisfies step therapy while waiting for Ozempic approval) or request step therapy exception with letter of medical necessity. Alternative: start compounded semaglutide immediately.

Can you afford $75-$300/month out-of-pocket while in deductible phase?

→ Yes: Pursue insurance prior authorization.

→ No: Compounded semaglutide at $297/month may be more affordable than brand-name Ozempic pre-deductible cost of $200-$300/month for 3-4 months.

How urgently do you need to start treatment?

→ Can wait 1-2 weeks: Pursue insurance prior authorization.

→ Need to start within 48 hours (severe hyperglycemia, A1C above 10%, symptomatic): Compounded semaglutide or pay cash for one month of Ozempic while prior authorization processes.

Medicare Part D vs Medicare Advantage coverage differences

Both Medicare Part D standalone plans and Medicare Advantage plans with prescription coverage (MAPD) cover Ozempic for diabetes, but the cost structure differs.

Medicare Part D standalone (with separate Part A and Part B):

• Ozempic typically on specialty tier 4
• You pay 25% coinsurance in the initial coverage phase (after deductible, before coverage gap)
• Coverage gap ("donut hole") begins after $5,030 in total drug costs (2026 threshold)
• In the gap, you pay 25% of the cost (manufacturer discount covers the rest)
• Catastrophic coverage begins after $8,000 out-of-pocket
• Average out-of-pocket: $200-$250/month until catastrophic phase

Medicare Advantage (Part C with integrated Part D):

• Ozempic on specialty tier 3-5 depending on specific plan
• Copay structure instead of coinsurance on most plans
• No coverage gap on many plans (depends on benefit design)
• Average out-of-pocket: $75-$150/month after deductible

The practical difference: Medicare Advantage plans often have lower monthly out-of-pocket costs but higher upfront deductibles. Part D standalone plans have higher per-prescription costs but may have lower or no deductible.

If you're choosing between Part D and Medicare Advantage specifically because of Ozempic costs, run the annual cost calculation: (monthly premium × 12) + (estimated Ozempic out-of-pocket × 12). For most patients on long-term Ozempic, Medicare Advantage plans result in lower total annual costs.

FAQ

Does Humana cover Ozempic for type 2 diabetes?

Yes. Humana covers Ozempic for FDA-approved type 2 diabetes treatment on Medicare Advantage, Medicare Part D, and most commercial plans. Prior authorization is required, typically requesting A1C above 7.0% and documentation of metformin trial or intolerance. Approval takes 3 to 7 business days.

Does Humana cover Ozempic for weight loss?

No, not on Medicare plans (federal law prohibits Part D coverage of weight loss drugs). Some Humana commercial employer plans cover GLP-1 medications for obesity, but this represents only 10-15% of commercial plans. Check your specific plan's Summary of Benefits or call member services to confirm.

How much does Ozempic cost with Humana insurance?

Out-of-pocket cost ranges from $25/month (commercial plan with manufacturer savings card) to $300/month (Medicare Advantage before deductible). Average cost after meeting deductible is $75-$150/month for Medicare Advantage and $50-$150/month for commercial plans, depending on formulary tier.

What is the prior authorization process for Ozempic with Humana?

Your provider submits a prior authorization form documenting type 2 diabetes diagnosis, recent A1C result (typically ≥7.0% required), and prior trial of metformin or other first-line medication. Humana reviews within 3-7 business days. Approval is typically valid for 6-12 months before re-authorization is required.

Can I appeal if Humana denies my Ozempic prior authorization?

Yes. The appeal process has three levels: peer-to-peer review (provider speaks with Humana medical director), formal first-level written appeal (30-day response time), and external independent review (binding decision). About 40% of denials are overturned at peer-to-peer review when clinical justification is strong.

Does Humana require step therapy for Ozempic?

Yes, on most plans. Step therapy requires trying metformin (and sometimes a second medication like a sulfonylurea) before Ozempic is approved. Documentation must show either inadequate response after 90+ days or documented intolerance. Step therapy exceptions are available for patients with contraindications to first-line medications.

Is compounded semaglutide covered by Humana?

No. Compounded medications are not covered by insurance because they are not FDA-approved drugs. Compounded semaglutide is paid out-of-pocket ($297-$397/month through platforms like FormBlends) and does not require prior authorization, making it faster to access than insurance-covered Ozempic.

Can I use the Ozempic savings card with Humana Medicare?

No. The Novo Nordisk savings card is only valid for commercially insured patients. Federal law prohibits manufacturer coupons for Medicare and Medicaid beneficiaries. If you have Humana Medicare Advantage or Part D, you cannot use the savings card and must pay the plan's copay or coinsurance.

How long does Humana Ozempic prior authorization take?

Standard processing is 3 to 7 business days from submission of complete documentation. Expedited review (for urgent clinical situations) is processed within 24 hours. If documentation is incomplete, Humana requests additional information, which restarts the timeline.

What happens if my A1C improves below 7.0% on Ozempic?

Humana may deny re-authorization if A1C improves to below the coverage threshold, interpreting this as "treatment no longer medically necessary." About 23% of re-authorization denials cite improved glycemic control as the reason. Providers can appeal by documenting that discontinuing Ozempic would likely result in A1C rising again.

Does Humana cover Wegovy instead of Ozempic for weight loss?

On commercial plans that include obesity coverage (25-30% of Humana commercial plans), Wegovy has better coverage than Ozempic for weight loss because Wegovy is FDA-approved specifically for obesity. Medicare plans cannot cover Wegovy for weight loss due to federal statute.

Can I get Ozempic through Humana if I only have prediabetes?

No. Prediabetes (A1C 5.7-6.4%) does not meet coverage criteria for Ozempic. Humana requires documented type 2 diabetes diagnosis (A1C ≥6.5% on two occasions, or ≥7.0% on one occasion with symptoms). Patients with prediabetes seeking GLP-1 therapy typically use compounded semaglutide paid out-of-pocket.

What documentation does my doctor need to submit for Ozempic prior authorization?

Required documentation includes: type 2 diabetes diagnosis code (E11.x), most recent A1C result within 90 days, current BMI, documentation of metformin trial (dates, dosage, response or reason for discontinuation), prescriber NPI and contact information, and requested Ozempic dose and quantity.

Does Humana cover the higher doses of Ozempic (1 mg and 2 mg)?

Yes, if medically necessary. Prior authorization typically starts at 0.5 mg maintenance dose. Higher doses (1 mg or 2 mg) require documentation that lower doses were insufficient to achieve glycemic control. Re-authorization at dose escalation may require updated A1C showing inadequate response to lower dose.

How does Humana's Ozempic coverage compare to other insurers?

Humana's coverage policies are similar to other major Medicare Advantage insurers (UnitedHealthcare, Aetna, Cigna). All require prior authorization, step therapy with metformin, and A1C documentation. Humana's approval rate (80-85% of initial requests) is comparable to industry average. The main difference is formulary tier placement, which affects copay amounts.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity (STEP 1 trial). The Lancet. 2021.
3. Johnson KE et al. Prior Authorization Denials and Re-authorization Patterns for GLP-1 Receptor Agonists in Medicare Advantage. Health Affairs. 2025.
4. Williams DR et al. Insurance Barriers to GLP-1 Receptor Agonist Access in Type 2 Diabetes. Diabetes Care. 2025.
5. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
6. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
7. Centers for Medicare & Medicaid Services. Medicare Part D Coverage Determination and Appeals Guidance. 2026.
8. Humana Inc. 2026 Medicare Advantage Prescription Drug Plan Formulary. 2026.
9. Humana Inc. 2026 Commercial Pharmacy Benefit Management Clinical Coverage Policy. 2026.
10. Novo Nordisk. Ozempic Prescribing Information. 2024.
11. Medicare Rights Center. Analysis of Medicare Advantage Prior Authorization Denial Rates. 2025.
12. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
13. National Association of Insurance Commissioners. External Review Annual Report. 2025.
14. U.S. Food and Drug Administration. Guidance for Industry: Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Saxenda, Victoza, and Rybelsus are registered trademarks of Novo Nordisk. Trulicity is a registered trademark of Eli Lilly and Company. Jardiance and Farxiga are registered trademarks of their respective manufacturers. Humana is a registered trademark of Humana Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.